Assignee
IMMUNOVACCINE TECHNOLOGIES INC
CA·18 granted patents·17 pending applications·167 citations·filing 2001–2022
Top patents by PatentIndex Score
35 records- 0195US10272042B2Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatmentIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Apr 30, 2019·41 cites·61 claims
- 0294US6793923B2Vaccines with enhanced immune response and methods for their preparationIMMUNOVACCINE TECHNOLOGIES INC·Filed 2001·Granted Sep 21, 2004·69 cites·14 claims
- 0389US7824686B2Vaccines with enhanced immune response and methods for their preparationIMMUNOVACCINE TECHNOLOGIES INC·Filed 2008·Granted Nov 2, 2010·12 cites·20 claims
- 0487US7056515B2Antigens for immunocontraceptionIMMUNOVACCINE TECHNOLOGIES INC·Filed 2003·Granted Jun 6, 2006·18 cites·19 claims
- 0584US10232052B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Mar 19, 2019·4 cites·27 claims
- 0683US11260116B2Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2017·Granted Mar 1, 2022·2 cites·22 claims
- 0783US11235069B2Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Feb 1, 2022·1 cites·27 claims
- 0882US10729766B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Aug 4, 2020·1 cites·28 claims
- 0982US9925142B2Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatmentIMMUNOVACCINE TECHNOLOGIES INC·Filed 2015·Granted Mar 27, 2018·4 cites·6 claims
- 1082US9114174B2Vaccines with enhanced immune response and methods for their preparationIMMUNOVACCINE TECHNOLOGIES INC·Filed 2013·Granted Aug 25, 2015·4 cites·10 claims
- 1179US10988500B2Lipid A mimics, methods of preparation, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Apr 27, 2021·1 cites·22 claims
- 1279US10105435B2Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2012·Granted Oct 23, 2018·5 cites·20 claims
- 1376US11406705B2Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjectsIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Aug 9, 2022·2 cites·20 claims
- 1470US10022441B2Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2013·Granted Jul 17, 2018·1 cites·29 claims
- 1569US2021322573A1Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivoIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1666US11160861B2Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvantIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Granted Nov 2, 2021·1 cites·28 claims
- 1766US10533033B2Lipid A mimics, methods of preparation, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2015·Granted Jan 14, 2020·1 cites·35 claims
- 1865US11717563B2Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substanceIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Granted Aug 8, 2023·0 cites·26 claims
- 1965US11077184B2Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune responseIMMUNOVACCINE TECHNOLOGIES INC·Filed 2018·Granted Aug 3, 2021·0 cites·21 claims
- 2065US2011070298A1Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic SubstanceIMMUNOVACCINE TECHNOLOGIES INC·Filed 2009·Application pending·0 cites
- 2164US2021052724A1Method for improving the efficacy of a survivin vaccine in the treatment of cancerIMMUNOVACCINE TECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 2264US2022143165A1Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 2364US2021308252A1Liposome compositions comprising pam2cys or pam3cys adjuvant and methods for inducing a humoral immune responseIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 2461US2024390468A1Survivin and mage-a9 dual-targeted immunotherapyIMMUNOVACCINE TECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 2560US2010209452A1Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2008·Application pending·0 cites
- 2658US2022001010A1Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvantIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 2757US2023381309A1Methods of treating diffuse large b-cell lymphomaIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 2854US2009297593A1Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase as a Vehicle for Cancer TreatmentIMMUNOVACCINE TECHNOLOGIES INC·Filed 2006·Application pending·0 cites
- 2953US2023355526A1Lipid compositions comprising polynucleotide antigensIMMUNOVACCINE TECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 3051US2022125903A1Methods for improving the efficacy of a survivin therapeutic in the treatment of tumorsIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Application pending·0 cites
- 3148US2023000769A1Oil-in-water emulsion formulations for delivery of active or therapeutic agentsIMMUNOVACCINE TECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 3248US2021147544A1Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodesIMMUNOVACCINE TECHNOLOGIES INC·Filed 2019·Application pending·0 cites
- 3343US2020230057A1Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses ThereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2017·Application pending·0 cites
- 3443US2020353062A1Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereofIMMUNOVACCINE TECHNOLOGIES INC·Filed 2017·Application pending·0 cites
- 3540US2018162913A1Methods for potentiating an immune response using depot-forming and non-depot-forming vaccinesIMMUNOVACCINE TECHNOLOGIES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when IMMUNOVACCINE TECHNOLOGIES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →